119 related articles for article (PubMed ID: 21040319)
1. A rapid infusion protocol is safe for total dose iron polymaltose: time for change.
Garg M; Morrison G; Friedman A; Lau A; Lau D; Gibson PR
Intern Med J; 2011 Jul; 41(7):548-54. PubMed ID: 21040319
[TBL] [Abstract][Full Text] [Related]
2. Delayed adverse reactions to total-dose intravenous iron polymaltose.
Haines ML; Gibson PR
Intern Med J; 2009 Apr; 39(4):252-5. PubMed ID: 19402865
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy.
Khalafallah A; Dennis A; Bates J; Bates G; Robertson IK; Smith L; Ball MJ; Seaton D; Brain T; Rasko JE
J Intern Med; 2010 Sep; 268(3):286-95. PubMed ID: 20546462
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
6. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
[TBL] [Abstract][Full Text] [Related]
7. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
8. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
10. Safety of iron polymaltose given as a total dose iron infusion.
Newnham E; Ahmad I; Thornton A; Gibson PR
Intern Med J; 2006 Oct; 36(10):672-4. PubMed ID: 16958647
[TBL] [Abstract][Full Text] [Related]
11. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of total dose intravenous iron infusion in the treatment of iron-deficiency anemia in adult non-pregnant patients].
Reynoso-Gómez E; Salinas-Rojas V; Lazo-Langner A
Rev Invest Clin; 2002; 54(1):12-20. PubMed ID: 11995402
[TBL] [Abstract][Full Text] [Related]
14. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
Gilmartin CE; Hoang T; Cutts BA; Leung L
Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of iron polymaltose infusions.
Lee AYS; Leung SHP
Hosp Pract (1995); 2019 Apr; 47(2):96-98. PubMed ID: 30882255
[TBL] [Abstract][Full Text] [Related]
16. Rapid iron infusion with iron polymaltose: further improvements may be possible.
Tampi R; Herrmann R; Barr A; Wright M
Intern Med J; 2012 Jan; 42(1):111. PubMed ID: 22276566
[No Abstract] [Full Text] [Related]
17. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.
Schröder O; Schrott M; Blumenstein I; Jahnel J; Dignass AU; Stein J
Z Gastroenterol; 2004 Aug; 42(8):663-7. PubMed ID: 15314711
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation.
Mudge DW; Tan KS; Miles R; Johnson DW; Badve SV; Campbell SB; Isbel NM; van Eps CL; Hawley CM
Transplantation; 2012 Apr; 93(8):822-6. PubMed ID: 22290270
[TBL] [Abstract][Full Text] [Related]
20. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
